NCT03762096View on ClinicalTrials.gov

Short Interval Resveratrol Trial in Cardiovascular Surgery

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

April 16, 2021

Study Completion Date

December 31, 2026

Conditions
Diabetes Mellitus, Type 2Coronary Artery Disease
Interventions
DIETARY_SUPPLEMENT

Trans-resveratrol

1 gram, twice a day by mouth Transmax (Biotivia)

DIETARY_SUPPLEMENT

Placebo

Placebo

Trial Locations (1)

04102

Maine Medical Center, Portland

Sponsors

Lead Sponsor

MaineHealth
All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

MaineHealth

OTHER

NCT03762096 - Short Interval Resveratrol Trial in Cardiovascular Surgery | Biotech Hunter | Biotech Hunter